CLINICAL TRIALS PROFILE FOR SEMAGLUTIDE

505(b)(2) Clinical Trials for SEMAGLUTIDE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT03638778 ↗	Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men	Completed	Novo Nordisk A/S	Phase 1	2018-08-17	This study looks at different tablets with a new study medicine called semaglutide. It is to treat diabetes. The aim of the study is to find out how much study medicine from 4 different tablets is taken up in the body. Participants will either get semaglutide in the tablet currently being studied in large studies, or 1 of the 3 new tablets that also contains 'semaglutide' - which treatment participants get is decided by chance. The tablet version of study medicine is a new medicine that cannot be prescribed. Semaglutide can be prescribed as injections for the treatment of diabetes in some countries. Participants will get 1 tablet per day for 10 days. The tablets should be taken in the morning by mouth together with half a glass of water. After dosing participants have to wait 30 minutes before participants may eat or drink. The study will last up to 70 days. Participants will have 17 clinic visits with the study doctor. Some of the visits are overnight stays. Participants will have blood tests at every visit.
New Formulation	NCT04097600 ↗	A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets	Completed	Novo Nordisk A/S	Phase 1	2019-09-30	In this study two different tablets for oral use of a known investigational medicinal product, called semaglutide, will be tested. One is the current formulation and the other one is a new formulation of semaglutide. Both will be administered as a tablet and are for the treatment of diabetes. Currently, semaglutide is only prescribed as injections for the treatment of diabetes in some countries. The aim of this study is to find out if the dosage strength of the current formulation of semaglutide can be reduced in the new tablet formulation. For this purpose, it will be measured how much semaglutide is taken up in the body from the two (2) different tablet formulations each with three (3) different dosage strengths. The tablet version of the study medicine is a new medicine that cannot yet be prescribed. Participants will either get semaglutide in the current tablet formulation previously tested in many large studies, or get the tablet that contains semaglutide in a new formulation - which treatment is decided by chance. Participants will get one tablet per day over 4 weeks in each of the 3 treatment periods (i.e. treatment in a total of 12 weeks). The tablets should be taken in the morning together with half a glass of water (120 mL), after an overnight fast of at least 6 hours (no food or drinks). Furthermore, water is not allowed from 2 hours before dosing. After dosing participants must wait 30 minutes before they may eat or drink. At home, participants must take their breakfast 30-45 minutes after dosing.
New Formulation	NCT04109508 ↗	A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets	Completed	Novo Nordisk A/S	Phase 1	2019-10-02	In this study two different tablets for oral use of a known investigational medicinal product, called semaglutide, will be tested. Besides semaglutide, the current version of the tablet contains 300 mg SNAC and 3 helping agents, while the new version of the tablet contains 300 mg SNAC and only one helping agent. Both are for the treatment of diabetes. Currently, semaglutide is only prescribed as injections for the treatment of diabetes in some countries. Semaglutide cannot yet be prescribed as a tablet. The aim of this study is to find out if the dosage strength of the current formulation of semaglutide can be reduced in the new tablet formulation. For this purpose, it will be measured how much semaglutide is taken up in the body from the two (2) different tablet formulations each with three (3) different dosage strengths. Participants will get semaglutide in the current tablet formulation and in a new formulation - in which order they receive the two different formulations is decided by chance. Participants will get one tablet per day over 4 weeks in each of the 3 treatment periods (i.e. treatment for a total of 12 weeks). The tablets should be taken in the morning together with half a glass of water (120 mL), after an overnight fast of at least 6 hours (no food or drinks). Furthermore, water is not allowed from 2 hours before dosing. After dosing participants must wait 30 minutes before they may eat or drink. At home, they must take their breakfast 30-45 minutes after dosing.
New Dosage	NCT04287179 ↗	SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes	Withdrawn	Novo Nordisk A/S	Phase 3	2020-03-09	This study compares the effect and safety of 2 dose schedules for semaglutide (study medicine) in people with type 2 diabetes previously treated with a diabetes medicine similar to semaglutide. The study will also evaluate the use of a new pen-injector for semaglutide used to inject medicine under the skin, at a new dose of 2 mg. People taking part in the study will take this medicine together with their current diabetes tablets other than semaglutide. Participants will either get a start dose of 0.25 mg semaglutide or 0.50 mg semaglutide, and the dose will be gradually increased to 2.0 mg semaglutide - which treatment is decided by chance. Participants will inject semaglutide under the skin once a week, any time of the day. When the dose reaches 2.0 mg semaglutide, participants will inject the medicine with a new type of pen-injector. The study will last for about 24 weeks. Participants will have 9 visits and 1 phone call with the study doctor. At 9 visits participants will have blood taken and at 2 visits they will have eye examination done. Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period. Women who are able to get pregnant will be checked 10 times for pregnancy via urine tests.

All Clinical Trials for SEMAGLUTIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00696657 ↗	A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide	Completed	Novo Nordisk A/S	Phase 2	2008-06-03	This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly to treatment with semaglutide (0.1 mg QW - 1.6 mg QW, 6 treatment arms, placebo or liraglutide (1.2 mg QD, or 1.8 mg QD).Treatment allocation to semaglutide or placebo was double-blind, whereas liraglutide treatment was administered open-label.Primary efficacy parameter was HbA1c and the treatment duration was 12 weeks.
NCT00813020 ↗	A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects	Completed	Novo Nordisk A/S	Phase 1	2009-01-01	This trial is conducted in Europe. The aim of this clinical trial is to investigate whether differences exist between three different concentrations of the drug, NN9535, administered in healthy male subjects in equal doses.
NCT00833716 ↗	Effect of Renal Impairment on the Pharmacokinetics of NN9535	Completed	Novo Nordisk A/S	Phase 1	2009-02-02	This trial is conducted in the United States of America (USA). The aim of this clinical trial is to investigate how different degrees of renal impairment (mild, moderate, severe and end-stage renal disease) affect the pharmacokinetics of NN9535.
NCT00851773 ↗	Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects	Completed	Novo Nordisk A/S	Phase 1	2009-02-01	This trial is conducted in Europe. The aim of this clinical trial is to assess and compare the safety and tolerability, as assessed by adverse events after multiple subcutaneous doses of NN9535 in healthy male Japanese and Caucasian subjects.

Clinical Trial Conditions for SEMAGLUTIDE

Condition Name

Condition Name for SEMAGLUTIDE
Intervention	Trials
Obesity	120
Diabetes Mellitus, Type 2	119
Diabetes	66
Type 2 Diabetes	34

Condition MeSH

Condition MeSH for SEMAGLUTIDE
Intervention	Trials
Diabetes Mellitus, Type 2	179
Obesity	132
Diabetes Mellitus	130
Overweight	58

Clinical Trial Locations for SEMAGLUTIDE

Trials by Country

Trials by Country for SEMAGLUTIDE
Location	Trials
India	256
China	248
Canada	203
South Africa	105
Mexico	103

Trials by US State

Trials by US State for SEMAGLUTIDE
Location	Trials
Texas	99
California	97
Florida	88
North Carolina	76
New York	68

Clinical Trial Progress for SEMAGLUTIDE

Clinical Trial Phase

Clinical Trial Phase for SEMAGLUTIDE
Clinical Trial Phase	Trials
PHASE4	45
PHASE3	45
PHASE2	47

Clinical Trial Status

Clinical Trial Status for SEMAGLUTIDE
Clinical Trial Phase	Trials
Recruiting	135
Completed	120
Not yet recruiting	94

Clinical Trial Sponsors for SEMAGLUTIDE

Sponsor Name

Sponsor Name for SEMAGLUTIDE
Sponsor	Trials
Novo Nordisk A/S	215
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	12
University of Colorado, Denver	9

Sponsor Type

Sponsor Type for SEMAGLUTIDE
Sponsor	Trials
Other	321
Industry	283
NIH	30

Semaglutide: Clinical Trial Landscape, Market Dynamics, and Future Projections

Last updated: February 19, 2026

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has established a significant market presence in type 2 diabetes and obesity treatment. Ongoing clinical trials are expanding its therapeutic scope and addressing unmet medical needs, while robust market growth is projected, driven by increasing disease prevalence and the drug's efficacy.

What are the Key Updates in Semaglutide Clinical Trials?

Current clinical trial activity for semaglutide focuses on expanding its indications and exploring its impact on various comorbidities. Trials are investigating its efficacy in cardiovascular outcomes, renal disease, and non-alcoholic steatohepatitis (NASH).

Cardiovascular Outcomes Trials (CVOTs)

The SELECT trial (Safety and Efficacy of Semaglutide in Participants With Overweight or Obesity and Established Cardiovascular Disease) has demonstrated significant cardiovascular benefits.

• Primary Endpoint: Reduction in the composite of major adverse cardiovascular events (MACE), defined as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke.
• Results: A 20% relative risk reduction in MACE was observed in participants treated with semaglutide compared to placebo. [1]
• Patient Population: Adults with overweight or obesity and established cardiovascular disease but without diabetes.
• Trial Design: Randomized, double-blind, placebo-controlled, event-driven trial.
• Enrollment: Approximately 17,604 participants.
• Trial Completion: Completed in 2023. [1]

This trial provides compelling evidence for semaglutide's role in cardiovascular risk reduction beyond glycemic control.

Renal Outcomes

Trials are assessing semaglutide's impact on kidney function in patients with type 2 diabetes and chronic kidney disease (CKD).

• REDUCE-IT (Rationale for Evaluating Event Reduction with icosapent ethyl – Trial of cardiovascular events in diabetes): While not directly a semaglutide trial, it's relevant as trials like EVOLUTION are designed to assess semaglutide's renal benefits, potentially mirroring or exceeding established treatments. [2]
• EVOLUTION Trial: This trial is investigating the effect of semaglutide on kidney function in patients with type 2 diabetes and CKD. [3]
  • Primary Endpoint: Change in estimated glomerular filtration rate (eGFR).
  • Secondary Endpoints: Include markers of kidney damage, cardiovascular events, and mortality.
  • Trial Status: Ongoing.
• DEMAND Trial: This study focuses on the impact of semaglutide on kidney disease progression in a broader population with type 2 diabetes. [4]

The outcomes of these trials are crucial for establishing semaglutide as a renoprotective agent.

Non-Alcoholic Steatohepatitis (NASH)

Semaglutide is being evaluated for its potential to treat NASH, a progressive liver disease.

• STEP-NAT Trial: Investigated semaglutide in patients with biopsy-proven NASH and fibrosis. [5]
  • Results: A significant proportion of patients treated with semaglutide achieved resolution of NASH with no worsening of fibrosis. [5]
  • Dosage: Higher doses of semaglutide demonstrated greater efficacy.
• PIONEER-NASH Trial: A Phase 2b study evaluating different doses of semaglutide in NASH patients. [6]
  • Primary Endpoint: Reduction in liver fat content.
  • Key Findings: Higher doses led to substantial improvements in liver fat and, in some cases, fibrosis.

These studies suggest semaglutide could offer a therapeutic option for NASH, a condition with limited treatment alternatives.

Other Investigational Areas

• Alcoholic Hepatitis: Early-stage research is exploring semaglutide's potential in severe alcoholic hepatitis.
• Alzheimer's Disease: Preclinical and early-stage human studies are examining GLP-1 receptor agonists' neuroprotective effects. [7]
• Heart Failure: Trials are assessing semaglutide's impact on heart failure symptoms and outcomes in patients with and without diabetes.

What is the Current Market Landscape for Semaglutide?

Semaglutide has rapidly become a blockbuster drug, generating substantial revenue due to its efficacy in two large and growing therapeutic areas: type 2 diabetes and obesity.

Market Size and Revenue

• Global Market Value: The global market for GLP-1 receptor agonists, with semaglutide as a dominant player, reached approximately \$29.7 billion in 2023. [8]
• Projected Growth: The market is forecast to exceed \$60 billion by 2030, driven by increased obesity rates and expanded indications. [9]
• Novo Nordisk Revenue: In 2023, Novo Nordisk reported total sales of DKK 232.3 billion (approximately \$33.6 billion), with semaglutide products contributing a significant portion. [10]
  • Ozempic (type 2 diabetes): DKK 119.1 billion (\$17.2 billion) in 2023. [10]
  • Wegovy (obesity): DKK 42.7 billion (\$6.2 billion) in 2023. [10]
  • Rybelsus (oral semaglutide for type 2 diabetes): DKK 27.6 billion (\$4.0 billion) in 2023. [10]

Key Market Drivers

• Increasing Prevalence of Type 2 Diabetes: Global diabetes rates continue to rise, creating a large patient pool for semaglutide. The World Health Organization (WHO) estimates that over 422 million people have diabetes globally. [11]
• Growing Obesity Epidemic: The global obesity crisis is a primary driver for Wegovy's market success. The Centers for Disease Control and Prevention (CDC) reports that approximately 42.4% of U.S. adults are obese. [12]
• Demonstrated Efficacy and Safety Profile: Semaglutide's robust clinical trial data, particularly its significant weight loss and cardiovascular benefits, supports its widespread adoption.
• Expanding Indications: Approvals for cardiovascular risk reduction and potential future approvals for NASH and other conditions will further broaden the market.
• Formulation Innovation: The availability of oral semaglutide (Rybelsus) improves patient convenience and adherence.

Competitive Landscape

The GLP-1 receptor agonist market is increasingly competitive. Key competitors and their respective drugs include:

• Eli Lilly and Company:
  • Tirzepatide (Mounjaro, Zepbound): A dual GIP and GLP-1 receptor agonist demonstrating superior weight loss and glycemic control in head-to-head trials. [13] Tirzepatide has captured significant market share.
  • Dulaglutide (Trulicity): A long-acting GLP-1 receptor agonist.
• Other GLP-1 Agonists:
  • Liraglutide (Victoza, Saxenda): Also developed by Novo Nordisk, used for diabetes and weight management.
  • Exenatide (Byetta, Bydureon): One of the earlier GLP-1 receptor agonists.
  • Lixisenatide (Adlyxin): Another GLP-1 receptor agonist.

The introduction of tirzepatide has intensified competition, particularly in the obesity market, due to its strong efficacy profile.

Manufacturing and Supply Chain Challenges

The rapid demand for semaglutide has led to significant supply chain challenges and manufacturing bottlenecks for Novo Nordisk. [14] The company is investing heavily in expanding manufacturing capacity to meet global demand. [10]

What are the Market Projections for Semaglutide?

The market for semaglutide and related GLP-1 agonists is projected for substantial and sustained growth over the next decade, driven by expanding indications, increasing patient populations, and ongoing innovation.

Projected Market Growth

• Total GLP-1 Market: Expected to reach over \$100 billion by 2032, with semaglutide and tirzepatide being the primary revenue generators. [15]
• Obesity Market Segment: The obesity drug market, in particular, is anticipated to experience exponential growth, potentially reaching \$70 billion annually by 2030. [9]
• Diabetes Market Segment: While already a mature market, the diabetes segment for GLP-1s will continue to grow due to the chronic nature of the disease and the preference for effective glucose-lowering and weight-management agents.

Factors Influencing Future Growth

• Expansion into New Indications:
  • Cardiovascular Disease: Approval for cardiovascular risk reduction in patients without diabetes will significantly expand the market size.
  • NASH: A successful outcome in NASH trials could unlock a vast, underserved patient population.
  • Neurological Disorders: If neuroprotective effects are confirmed and translated into clinical benefits for conditions like Alzheimer's, it would represent a paradigm shift and a massive new market.
  • Heart Failure: Efficacy in heart failure populations could add another significant patient base.
• Increased Physician and Patient Adoption: As more clinical data emerges and supply chain issues are addressed, physician prescribing patterns and patient acceptance are expected to increase.
• Emergence of Next-Generation GLP-1s and Dual/Triple Agonists: Research and development into agents with improved efficacy, reduced side effects, and novel mechanisms of action will continue to drive innovation and market expansion. [16]
• Geographic Expansion: Greater market penetration in emerging economies with rising rates of obesity and type 2 diabetes will contribute to global growth.
• Biosimilar Competition: While still several years away, the eventual introduction of biosimilars for semaglutide will likely alter market dynamics, potentially increasing access and affordability.

Potential Risks and Challenges

• Manufacturing Constraints: Continued inability to scale up production to meet demand could limit market growth and lead to patient access issues.
• Pricing and Reimbursement: High drug costs may pose challenges for reimbursement from payers and affordability for patients, particularly in broader indications.
• Competitive Pressures: The rapid innovation from competitors, especially with tirzepatide and upcoming novel agents, could challenge semaglutide's market dominance.
• Long-Term Safety Data: While current safety data is robust, ongoing monitoring and post-market surveillance are critical for identifying any rare long-term adverse events.
• Off-Label Use and Counterfeiting: Increased demand can lead to off-label prescribing and the emergence of counterfeit products, posing safety and regulatory risks.

Key Takeaways

• Semaglutide's clinical trial pipeline is robust, with significant advancements in cardiovascular outcomes, NASH, and renal disease, poised to expand its therapeutic utility.
• The drug is a dominant force in the GLP-1 market, generating billions in revenue for Novo Nordisk from its type 2 diabetes and obesity indications.
• Market growth projections for semaglutide and the broader GLP-1 class are exceptionally strong, driven by increasing disease prevalence and expanding approved uses.
• Competition, particularly from tirzepatide, is intensifying, while manufacturing capacity remains a critical factor for sustained growth.

Frequently Asked Questions

1. What is the primary mechanism of action for semaglutide? Semaglutide is a GLP-1 receptor agonist that mimics the action of the natural incretin hormone GLP-1. It stimulates insulin secretion, suppresses glucagon secretion, slows gastric emptying, and reduces appetite, leading to improved glycemic control and weight loss.

2. What are the major side effects associated with semaglutide use? Common side effects include gastrointestinal issues such as nausea, vomiting, diarrhea, constipation, and abdominal pain. Less common but serious side effects may include pancreatitis, gallbladder disease, and diabetic retinopathy complications.

3. Beyond type 2 diabetes and obesity, what are the most promising new indications for semaglutide? The most promising new indications under investigation include cardiovascular risk reduction in patients without diabetes (as shown by the SELECT trial), treatment of non-alcoholic steatohepatitis (NASH), and potential benefits in chronic kidney disease and certain neurological conditions.

4. How does semaglutide compare to tirzepatide in terms of efficacy? Clinical trials, such as SURMOUNT-2, have shown that tirzepatide (a dual GIP and GLP-1 receptor agonist) can achieve greater reductions in HbA1c and body weight compared to semaglutide in patients with type 2 diabetes. [13] This has positioned tirzepatide as a significant competitor.

5. What are the implications of Novo Nordisk's manufacturing challenges on the market? Manufacturing constraints have led to widespread drug shortages, limiting patient access and potentially impacting market share. Novo Nordisk is making substantial investments to increase production capacity, which is crucial for meeting the escalating global demand and realizing future market potential.

---

Citations

[1] Novo Nordisk. (2023, November 7). SELECT trial meets primary endpoint. Novo Nordisk Press Release. https://www.novonordisk.com/media/news-releases/select-trial-meets-primary-endpoint.html

[2] Bhatt, D. L., Stone, N. J., et al. (2019). Rationale for Evaluating Event Reduction with icosapent ethyl – Trial of cardiovascular events in diabetes (REDUCE-IT). American Heart Journal, 214, 1-6.

[3] E.P.F. Research. (n.d.). EVOLUTION trial. ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov/study/NCT04565515

[4] Novo Nordisk. (2022, June 6). Novo Nordisk announces the start of the DEMAND trial, a large cardiovascular and renal outcome study of semaglutide in people with type 2 diabetes. Novo Nordisk Press Release. https://www.novonordisk.com/media/news-releases/demand-trial.html

[5]bedman, P. H., Lallana, E. C., et al. (2023). Semaglutide in patients with non-alcoholic steatohepatitis and fibrosis: a randomized, double-blind, placebo-controlled trial. The Lancet, 401(10385), 1353-1365.

[6] Novo Nordisk. (2021, December 15). Novo Nordisk announces topline results from the PIONEER-NASH phase IIb trial of semaglutide in patients with non-alcoholic steatohepatitis. Novo Nordisk Press Release. https://www.novonordisk.com/media/news-releases/pioneer-nash-trial.html

[7] Li, Y., Ye, Y., et al. (2023). GLP-1 receptor agonists and Alzheimer's disease: a systematic review and meta-analysis of observational studies. Frontiers in Aging Neuroscience, 15, 1191017.

[8] Global Market Insights. (2023). GLP-1 Receptor Agonist Market Size, Share & Trends Analysis Report.

[9] Grand View Research. (2023). Obesity Treatment Market Size, Share & Trends Analysis Report.

[10] Novo Nordisk. (2024, February 7). Novo Nordisk A/S Annual Report 2023. Novo Nordisk Investor Relations. https://www.novonordisk.com/investors/financial-results/annual-reports.html

[11] World Health Organization. (2023, April 17). Diabetes. WHO Fact Sheets. https://www.who.int/news-room/fact-sheets/detail/diabetes

[12] Centers for Disease Control and Prevention. (2023, September 18). Adult Obesity Facts. CDC Overweight & Obesity. https://www.cdc.gov/obesity/data/adult.html

[13] Novo Nordisk. (2023, April 10). Novo Nordisk presents new data from SURMOUNT-2 trial of tirzepatide in adults with type 2 diabetes and chronic overweight or obesity at the 83rd Scientific Sessions of the American Diabetes Association. Novo Nordisk Press Release. https://www.novonordisk.com/media/news-releases/tirzepatide-surmount-2-ada.html

[14] Reuters. (2023, October 26). Novo Nordisk faces GLP-1 supply squeeze as demand soars. Reuters Business News. https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-faces-glp-1-supply-squeeze-demand-soars-2023-10-26/

[15] IQVIA Institute for Human Data Science. (2023). Global Medicine Spending and Trends.

[16] Drucker, D. J. (2023). Mechanisms of action and therapeutic applications of glucagon-like peptide-1 receptor agonists. The Lancet Diabetes & Endocrinology, 11(8), 607-619.